2026· Advances in Pharmacology· Vol 106, pp.
179-212
· 0 citations
Medicine
TL;DR
The pharmacological imperative for transient CAR expression is delineated, including lipid nanoparticles in combination with mRNA, which avoids risks of insertional mutagenesis and enables titratable, short-lived CAR expression, thereby enhancing safety management and suitability for applications beyond oncology.
This review highlights key engineering strategies enabling in vivo CAR T-cell generation, summarizes emerging clinical research and development, and discusses future opportunities for expanding in vivo CAR T-cell therapies as scalable immunotherapy platforms.
Janani Gopalakrishnan, Bhagyashri Rathod, Sachin Puri· International Immunopharmaco...· 0 citations
In vivo CAR-T is poised to broaden the reach of cellular immunotherapy, provided that its development is guided by rigorous pharmacology, chemistry, manufacturing and controls, and long-term molecular safety surveillance.
Wan-Ting Wang, Yujia Cai, Xuanming Yang et al.· Immunity & Inflammation· 0 citations
A three-layer mechanistic framework is presented that reframes manufacturing as biology: integration biology determines genomic risk and transgene stability; clonal fitness shapes persistence, dominance, and exhaustion; and epigenomic imprinting preconfigures functional trajectories.
Duc-Hiep Bach, T. Nguyen· Human Gene Therapy· 0 citations
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Markus Barden, D. Harrer, Hinrich Abken· Expert Opinion on Biological...· 0 citations
If in-vivo CAR-T therapy approaches continue to mature, they may offer a more scalable, cost-effective, and accessible alternative to traditional ex vivo CAR-T therapy, though this remains a projected rather than demonstrated benefit.
Lia Bhatia· American Journal of Student...· 0 citations
The biological mechanisms underlying resistance to CAR-T therapy in solid tumors are examined and emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity are critically evaluated.
Wei Cheng, Mei-Lan Liu, Yu-Hua Diao et al.· Cancer Biome and Targeted Th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
